Evommune, Inc. 8-K

What Happened

• Evommune, Inc. (EVMN) filed a Form 8-K on February 10, 2026, announcing positive top-line data from its Phase 2a proof-of-concept trial (EVO301) in adult patients with moderate-to-severe atopic dermatitis (AD).
• The company furnished a press release (Exhibit 99.1) and a presentation (Exhibit 99.2) summarizing the results and will host a live webcast on February 10, 2026 to discuss the findings. The materials are furnished (not “filed”) under Regulation FD and the company notes it has no obligation to update Exhibit 99.2.

Key Details

• Filing date: February 10, 2026 (Form 8-K).
• Program: EVO301 Phase 2a trial in adult moderate-to-severe atopic dermatitis — top-line data described as positive (no efficacy or safety numbers disclosed in the 8-K).
• Materials: Press release (Exhibit 99.1) and investor presentation (Exhibit 99.2) provided; live webcast available on Evommune’s “News & Events” IR webpage.
• Corporate signatory: Form 8-K signed by Luis Peña, President and CEO.

Why It Matters

• Positive Phase 2a top-line results are a key clinical milestone that can de-risk EVO301’s development program and inform next steps (e.g., larger trials, regulatory discussions).
• Investors should watch the webcast and the accompanying presentation for detailed efficacy and safety data, timelines, and any guidance on next clinical or regulatory plans—details not included in the 8-K itself.
• There were no financial statements or other material corporate actions reported in this filing; the 8-K primarily communicates clinical progress and investor materials.